Novartis’s smokers’ cough treatment gets European nod

ZURICH (Reuters) – Swiss drugmaker Novartis said on Monday the European Commission had approved its Seebri Breezhaler as a once-daily treatment for adult patients with chronic obstructive pulmonary disease, more commonly known as smoker's cough, in the European Union. Trials showed that the treatment significantly improved lung function over the first four hours after morning dosing when compared to placebo, and that this benefit was sustained for 24 hours over a 52-week period, Novartis said. …